Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Omapatrilat

2

VIII.a Angioedema (may cause UAO, asphyxia and death)

2
Last update : 11/05/2015
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Neprilysin inhibition in chronic kidney disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2015 May;30;738-43 2015 May
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
American journal of hypertension 2004 Feb;17;103-11 2004 Feb
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Lancet (London, England) 2000 Aug 19;356;615-20 2000 Aug 19
Vasopeptidase inhibition and angio-oedema.
Lancet (London, England) 2000 Aug 19;356;608-9 2000 Aug 19

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies